Chinese Herbal Anti-Cancer Therapy Under Consideration For NIH Funding
This article was originally published in The Tan Sheet
Executive Summary
A Chinese herbal dietary supplement to treat advanced-stage lung cancer is being considered for funding by the National Institutes of Health. Institute representatives will report their findings to the newly-chartered Cancer Advisory Panel for Complementary and Alternative Medicine in December.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning